Abstract
The
Ten-Eleven Translocation-2
(
TET2
) gene, located on chromosome 4q24, has been implicated in hematological malignancies. The
TET2
gene shows mutations in variable myeloid malignancies with the involvement of 15% of myeloproliferative neoplasms (MPNs). The inactivation of the
TET2
gene in both mice and humans has shown a high degree of deregulation of the hematopoiesis process leading to hematological malignancies. Polycythemia vera (PV), an MPN characterized by increased red blood cell mass, has been associated with the
TET2
gene. Furthermore,
TET2
genes have been found to facilitate
Janus kinase-2
and signal transducer activator of transcription 5, as well as modulate the epigenetic composition of genomic DNA. However, little is known about the role of
TET2
mutations in patients with PV. Several studies have been conducted to further assess the significant role of
TET2
gene function in various disease processes and prognoses to enhance the management and care of these patients.